CCM
HBIO icon

Cribstone Capital Management’s Harvard Bioscience HBIO Stock Holding History

Cribstone Capital Management’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-260
Closed -$22K – 391
2021
Q2 		$22K Buy
+260
New +$18.4K 0.01% 204

Other funds holding HBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
HP
Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return

Cribstone Capital Management's HBIO Position: Q3 2021 in Review

Cribstone Capital Management sold out of Harvard Bioscience (HBIO) in Q3 2021, closing a stake of 260 shares — an estimated $22K sold.

Cribstone Capital Management first reported a position in HBIO in Q2 2021 and held it in 1 quarter. The position peaked at $22K in Q2 2021. 99 funds tracked by Wall St. Rank hold HBIO as of Q3 2021.

  • Cribstone Capital Management reported no remaining Harvard Bioscience position as of Q3 2021 after selling out during the quarter.
  • Cribstone Capital Management sold 260 Harvard Bioscience shares in Q3 2021, an estimated $22K.
  • Cribstone Capital Management first reported a position in Harvard Bioscience in Q2 2021 and held it in 1 quarter.
  • Cribstone Capital Management's Harvard Bioscience position peaked at $22K in Q2 2021.
  • 99 funds tracked by Wall St. Rank held Harvard Bioscience as of Q3 2021.

Based on Cribstone Capital Management's 13F filing for Q3 2021, filed 18 Nov 2021.